The oncology landscape is currently defined by the dominance of PD-1 inhibitors, a class of drugs that unmasks cancer cells to the immune system. But as patents for the industry’s most successful blockbusters approach their sunset, the race has shifted toward "bispecifics"—engineered antibodies capable of binding to two different targets simultaneously.
New data from Sino Biopharm, a partner of Merck & Co., offers an early look at this next chapter. Their experimental drug, MK-2010, targets both PD-1 and VEGF, a protein that stimulates the growth of blood vessels to feed tumors. In a small early-stage trial, six out of 11 lung cancer patients responded to a low dose of the therapy, providing a preliminary signal that hitting two pathways at once may be clinically viable.
This dual-action strategy seeks to overcome the resistance that often develops with single-target therapies. By simultaneously revving up the immune system and choking off the tumor’s nutrient supply, Merck and its partners are attempting to entrench their lead in a field that is becoming increasingly crowded with sophisticated biologics. While the patient cohorts remain small, the results mark a critical milestone in the transition from the era of the single antibody to the era of multi-functional molecular design.
With reporting from Endpoints News.
Source · Endpoints News
